Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

University Hospital Gasthuisberg

ESMO 33

12 - 16 Sep 2008

Published: 4 Dec 2008

Views: 15392

Rating:

Save

Prof. Eric Van Cutsem

K-Ras mutations and FOLFIRI plus cetuximab in mCRC.

Categories:
Colorectal & gastro

Related Videos

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

Maximising diagnosis of colon cancer with target screening

Dr Rimini Breakstone - Lifespan Cancer Institute, Rhode Island, USA

Maximising diagnosis of colon cancer with target screening ( Dr Rimini Breakstone - Lifespan Cancer Institute, Rhode Island, USA )

Optimising colon cancer care in Nigeria

Dr Rimini Breakstone - Lifespan Cancer Institute, Rhode Island, USA

Optimising colon cancer care in Nigeria ( Dr Rimini Breakstone - Lifespan Cancer Institute, Rhode Island, USA )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

Pembro plus gemcitabine and cisplatin potential option for metastatic or...

Dr Katie Kelley - University of California San Francisco, San Francisco, USA

Pembro plus gemcitabine and cisplatin potential option for metastatic or unresectable biliary tract cancer ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh...

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

More from ecancer